Kadimastem Ltd
Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a cli… Read more
Market Cap & Net Worth: Kadimastem Ltd (KMSTF)
Kadimastem Ltd (PINK:KMSTF) has a market capitalization of $14.98 Million ($14.98 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #30556 globally and #10066 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kadimastem Ltd's stock price $5.06 by its total outstanding shares 2960744 (2.96 Million).
Kadimastem Ltd Market Cap History: 2021 to 2025
Kadimastem Ltd's market capitalization history from 2021 to 2025. Data shows growth from $5.92 Million to $14.98 Million (765.38% CAGR).
Kadimastem Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kadimastem Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of KMSTF by Market Capitalization
Companies near Kadimastem Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to Kadimastem Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Kadimastem Ltd Historical Marketcap From 2021 to 2025
Between 2021 and today, Kadimastem Ltd's market cap moved from $5.92 Million to $ 14.98 Million, with a yearly change of 765.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $14.98 Million | -20.99% |
| 2024 | $18.96 Million | +885.23% |
| 2023 | $1.92 Million | 0.00% |
| 2022 | $1.92 Million | -67.50% |
| 2021 | $5.92 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Kadimastem Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $14.98 Million USD |
| MoneyControl | $14.98 Million USD |
| MarketWatch | $14.98 Million USD |
| marketcap.company | $14.98 Million USD |
| Reuters | $14.98 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.